Biotech Values

[DewDiligence]

IDIX catches a break to help offset
last week’s mishap with NM283:

http://yahoo.reuters.com/stocks/QuoteCompanyNewsArticle.aspx?storyID=urn:newsml:reuters.com:20060327...

>>
Novartis Files Telbivudine in China for Hep B

Mon Mar 27, 2006 12:58 AM ET

ZURICH, March 27 (Reuters) - Novartis < NVS > said it had filed its telbivudine drug for the treatment of patients with chronic hepatitis B for approval in China after data showed it was superior to the commonly used treatment lamivudine in Chinese patients.

A Phase III trial in China, a country estimated to have more than 120 million people infected with hepatitis B, showed that telbivudine provided a rapid and profound viral suppression, the Swiss drugmaker said on Monday in a statement.

The drug, previously known as LDT600, has already been filed in the United States and in the European Union.

Chronic hepatitis B, the world's most common serious liver infection, is a potentially fatal disease which is thought to affect over 350 million people worldwide.

Novartis is working with Idenix Pharmaceuticals Inc. < IDIX > on hepatitis B product candidates, including Telbivudine and Valtorcitabine, and has an exclusive option to license in Idenix's Valopicitabine or NM283, a hepatitis C treatment.

The chief executive of Idenix last month projected the global market for hepatitis B drugs would double to $2 billion by 2009, helped by the expected arrival of telbivudine and the expanded use and promotion of other new drugs.
<<